KOR Antagonist Therapy for Pain-Related Sleep Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic pain often ignore sleep disturbances or exacerbate them, and treatments for sleep issues do not improve chronic pain, creating a bidirectional relationship that affects mental and physical health, with kappa opioid receptor (KOR) signaling playing a central role in disrupting sleep and pain responses.
Innovation Solution
Administering a kappa opioid receptor (KOR) antagonist, such as nor-BNI, CYM53093, or CERC-501, to block KOR signaling, thereby treating secondary sleep disturbances induced by chronic pain or aging, improving sleep quality and reducing pain-related aversive qualities without affecting sensory pain perception.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If KOR agonists are used to treat chronic pain, then pain relief is achieved, but sleep disruption occurs
Solution Approach 1:
The patent segments the opioid receptor system into distinct types (mu, kappa, delta) and selectively targets the kappa receptor with antagonists, separating the pain modulation function from the sleep-disrupting function. This allows treatment of chronic pain while avoiding the sleep side effects associated with KOR agonists and other opioid treatments.
Solution Approach 2:
Instead of using KOR agonists that activate the receptor to treat pain, the patent inverts the approach by using KOR antagonists that block the receptor. This inversion prevents the maladaptive KOR signaling that causes sleep disruption while still addressing chronic pain through blocking the harmful dynorphin-KOR pathway.
2Object-affected harmful factors
If conventional pain treatments are administered, then pain management is improved, but sleep quality deteriorates
Solution Approach 1:
The patent introduces KOR antagonists as an intermediary mechanism that blocks the harmful interaction between dynorphin and KOR. This intermediary approach prevents the downstream effects of KOR activation that lead to sleep disruption, while still providing pain relief by blocking the maladaptive signaling pathway.
Solution Approach 2:
The patent changes the pharmacological parameter from KOR activation (agonism) to KOR blockade (antagonism). This parameter change fundamentally alters the therapeutic profile, providing pain relief without the sleep-disrupting effects that characterize conventional opioid treatments and KOR agonist therapy.
3Object-generated harmful factors
If sleep treatments are used to address sleep disturbances, then sleep quality improves, but chronic pain is not addressed
Solution Approach 1:
The patent applies KOR antagonism as a universal mechanism that simultaneously addresses both chronic pain and sleep disturbance. By blocking the KOR receptor, a single therapeutic approach provides dual benefits: pain relief through blocking maladaptive signaling and sleep improvement by preventing KOR-mediated sleep disruption.
4Object-affected harmful factors
If KOR signaling is activated to modulate pain, then pain response is altered, but sleep patterns are disrupted
Solution Approach 1:
The patent converts the harmful effect of KOR activation into a benefit by using KOR antagonists to block the receptor. The maladaptive KOR signaling that causes both pain and sleep problems is transformed into a therapeutic opportunity, where blocking the receptor provides relief from both conditions simultaneously.
Data Source
AI summary
Chronic pain patients complain about sleep disturbance with a high probability, while sleep loss increases pain in chronic pain patients. Sleep problems and pain promote a vicious spiral, suggesting a need for simultaneous treatment of both. The present invention provides a method to treat pain-related sleep disorders through distribution of a therapeutic amount of a KOR antagonist. The use of KOR antagonist could be a novel therapeutic agent for sleep disturbance in chronic pain patients. Additionally, KOR antagonists could be used to improve sleep in other conditions, such as depression or general anxiety disorder, where KOR signaling is induced.